Posaconazole for the prophylaxis of invasive fungal infection in patients receiving induction therapy for acute myeloid leukaemia

Trial Profile

Posaconazole for the prophylaxis of invasive fungal infection in patients receiving induction therapy for acute myeloid leukaemia

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jun 2015

At a glance

  • Drugs Posaconazole (Primary)
  • Indications Aspergillosis; Candidaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Apr 2014 New trial record
    • 10 Dec 2013 Results (n = 120) from two time periods (Jul2009-Jun2011 and Jul2011-Jun2013) presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top